Companies /Healthcare

Innoviva Inc

NASDAQ: INVA Biotechnology
$21.20
▲ $0.36 (+1.73%) today
Markets closed · 7:25pm ET
Today · % change

Fundamentals

Market Cap
$1.5B
P/E Ratio
4.8
Profit Margin
81.2%
Revenue (TTM)
$440.0M
EPS (TTM)
$4.30
52-Week Range
$17 – $25
Street Target
$35.00

About Innoviva

Innoviva Inc is a biopharmaceutical company focused on the development and commercialization of medicines for various respiratory conditions. Its portfolio includes RELVAR/BREO ELLIPTA and ANORO ELLIPTA for chronic obstructive pulmonary disease and asthma, as well as treatments for high blood pressure in shock patients and complicated intra-abdominal infections. Innoviva also works on developing new treatments, such as a potential single-dose cure for gonorrhea. Originally named Theravance, the company rebranded to Innoviva in 2016 and is based in Burlingame, California.

INVA Coverage